Abstract | OBJECTIVE: METHOD: RESULTS:
Fluoxetine monotherapy produced minimal improvement on various scales that rate severity of depression. The benefits of olanzapine monotherapy were modest. Olanzapine plus fluoxetine produced significantly greater improvement than either monotherapy on one measure and significantly greater improvement than olanzapine monotherapy on the other measures after 1 week. There were no significant differences between treatment groups on extrapyramidal measures nor significant adverse drug interactions. CONCLUSIONS:
Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.
|
Authors | R C Shelton, G D Tollefson, M Tohen, S Stahl, K S Gannon, T G Jacobs, W R Buras, F P Bymaster, W Zhang, K A Spencer, P D Feldman, H Y Meltzer |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 158
Issue 1
Pg. 131-4
(Jan 2001)
ISSN: 0002-953X [Print] United States |
PMID | 11136647
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Serotonin Uptake Inhibitors
- Fluoxetine
- Benzodiazepines
- Pirenzepine
- Olanzapine
|
Topics |
- Ambulatory Care
- Basal Ganglia Diseases
(chemically induced, epidemiology)
- Benzodiazepines
- Depressive Disorder
(drug therapy, psychology)
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Fluoxetine
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Olanzapine
- Pirenzepine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Selective Serotonin Reuptake Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|